Wednesday, March, 20, 2019 07:28:37

Saridon has earned the state of a heritage brand by being produced in India and trusted by customers of the country for the last 50 years.

Saridon pain relief tablet, developed by Piramal Enterprises Ltd (PEL), has recently been announced to be exempt from a list of debarred fixed dose combinations (FDCs), by a Supreme Court ruling.

According to an official press release by PEL, it was declared the company was granted a stay order from the Supreme Court on the ban in September 2018 that permitted the manufacturing, distribution and sale of Saridon. The press release mentions that Saridon is amongst the heritage analgesic brands in India, and one of the key products in PEL’s healthcare product portfolio that is widely trusted and enjoys strong customer loyalty globally.

Nandini Piramal, PEL Executive Director, has been reported by the Economic Times to be commenting on the Supreme Court ruling and say that PEL is pleased with the apex court ruling and sees it as an affirmation to the company’s commitment to provide valuable and safe healthcare solutions that fulfils unique needs of Indian consumers. She added that PEL was always confident that the law would prevail in Piramal’s favor.

For the record, in 2018 the Indian government banned 328 FDCs, terming them as ‘irrational’ due to their lack of therapeutic justification and safety issues.

Piramal has been reported in statement to say that Saridon has earned the state of a heritage brand by being produced in India and trusted by customers of the country for the last 50 years. The exemption from list of banned FDCs confirms the company’s intent of serving its customers with the highest levels of integrity. The statement further added Piramal will continue to develop its healthcare product portfolio intending to be among the top three over the-counter product companies in India by 2020.

PEL cited a study by AC Neilson and said that the analgesic market size in India is worth Rs 6,450 crore in which analgesic tablet market accounted for Rs 2,050 crore as of December 2018. Saridon has been estimated to be selling 31 tablets every second and is available in 9 lakh outlets across India.